AKT1 (6C1) Monoclonal Antibody

$Lane 1: HL-60 Cell lysates; probed with AKT1 (6C1) Monoclonal Antibody, unconjugated (bsm-51238M) at 1:5000 overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C.$

Lane 1: HL-60 Cell lysates; probed with AKT1 (6C1) Monoclonal Antibody, unconjugated (bsm-51238M) at 1:5000 overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C.

Applications

Reactivity

Human

Overview
Catalog #	bsm-51238M
Product Name	AKT1 (6C1) Monoclonal Antibody
Applications	WB
Reactivity	Human
Specifications
Conjugation	Unconjugated
Host	Mouse
Source	This AKT1 Monoclonal antibody is generated from mouses immunized with a KLH conjugated synthetic peptide selected from the 430-460 region of human AKT1.
Clonality	Monoclonal
Clone #	6C1
Isotype	IgG1
Concentration	0.5ug/ul
Purification	Mouse monoclonal antibody supplied in crude ascites with 0.09% (W/V) sodium azide.
Storage Buffer	0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage Condition	Store at -20°C for 12 months.
Target
Gene ID	207
Swiss Prot	P31749
Synonyms	AKT; PKB; RAC; CWS6; PRKBA; PKB-ALPHA; RAC-ALPHA; RAC-alpha serine/threonine-protein kinase; Protein kinase B; Protein kinase B alpha; PKB alpha; Proto-oncogene c-Akt; RAC-PK-alpha; AKT1
Background	The serine-threonine protein kinase encoded by the AKT1 gene is catalytically inactive in serum-starved primary and immortalized fibroblasts. AKT1 and the related AKT2 are activated by platelet-derived growth factor. The activation is rapid and specific, and it is abrogated by mutations in the pleckstrin homology domain of AKT1. It was shown that the activation occurs through phosphatidylinositol 3-kinase. In the developing nervous system AKT is a critical mediator of growth factor-induced neuronal survival. Survival factors can suppress apoptosis in a transcription-independent manner by activating the serine/threonine kinase AKT1, which then phosphorylates and inactivates components of the apoptotic machinery. Mutations in this gene have been associated with the Proteus syndrome. Multiple alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Jul 2011]
Application Dilution
WB	1:300-5000